Skip to main navigation menu Skip to main content Skip to site footer


Vol. 21 No. 1 (2023)

MJM MedTalks (S02E03): Beyond the Hype - GLP-1 Agonists Redefining Glycemic Control

  • Susan Joanne Wang, MSc, MDCM ▸
  • Dr Vanessa Tardio, MD
  • Dr Michael Tsoukas, MD
  • Katherine Lan, BScH
  • Vanessa Ross
  • Samy Amghar
  • Jan Pack, BSc, MSc
  • Masha (Maryia) Samuel, BSc
  • Renée-Claude Bider, BSc
  • Khiran Arumugam, BSc, MSc
  • Meryem K. Talbo, R.D., BSc, MSc
  • Predrag Jovanovic, BSc
April 23, 2024


McGill Journal of Medicine (MJM) MedTalks is a Podcast series where members of the medical and health science communities from McGill and beyond are interviewed on topics related to career, research, advocacy and more. The aim of MedTalks is to open a space where experienced professionals and researchers can share information and advice for trainees in healthcare and medical sciences. In this episode, Susan Wang, MJM Podcast Team Co-Lead and first year Internal Medicine Resident at McGill University interviews guest-experts and endocrinologists Dr. Michael Tsoukas, Assistant Professor in the Department of Medicine at McGill University, and Dr. Vanessa Tardio, Assistant Professor in the Department of Medicine and Program Director of the Endocrinology and Metabolism Residency Training Program at McGill University. This conversation covers GLP-1 agonists, what they are, their uses, the media hype, new and exciting research, and some advice for trainees. The show notes include a glossary of terms, links to publications referenced in the episode, and a full transcript of our conversation.


  1. Studies:
  2. Borlaug BA, Kitzman DW, Davies MJ, Rasmussen S, Barros E, Butler J, Einfeldt MN, Hovingh GK, Møller DV, Petrie MC, Shah SJ. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nature medicine. 2023 Sep;29(9):2358-65.
  3. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023 Dec 14;389(24):2221-32.
  4. McGuire DK, Busui RP, Deanfield J, Inzucchi SE, Mann JF, Marx N, Mulvagh SL, Poulter N, Engelmann MD, Hovingh GK, Ripa MS. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. Diabetes, Obesity and Metabolism. 2023 Jul;25(7):1932-41.
  5. Rossing, P., Baeres, F.M., Bakris, G., Bosch-Traberg, H., Gislum, M., Gough, S.C., Idorn, T., Lawson, J., Mahaffey, K.W., Mann, J.F. and Mersebach, H., 2023. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrology Dialysis Transplantation, 38(9), pp.2041-2051.
  6. News articles:
  7. How Kim Kardashian’s mystery weight loss to fit into Marilyn Monroe’s dress has led to a TikTok craze leading to shortages of a vital ‘miracle’ diabetes jab that battles clinical obesity:
  8. Proposed class action lawsuit filed against Canadian maker of popular weight loss drug Ozempic:
  9. Guidelines:
  10. Vallis TM, Macklin D, Russell-Mayhew S. Canadian Adult Obesity Clinical Practice Guidelines: Effective Psychological and Behavioural Interventions in Obesity Management. Available from:


Download data is not yet available.